ArticleEmerging microbes & infections2015
Antibacterial and anti-biofilm activities of thiazolidione derivatives against clinical staphylococcus strains.
Article in Emerging microbes & infections, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 48 citations in OpenAlex.
- Article
- Drug repurposing: a dual-mechanism antibiotic combats MRSA and its high resistant phenotypes.Frontiers in cellular and infection microbiology · 2026Article
- Repurposing bunamidine hydrochloride as a potent antimicrobial agent targeting vancomycin-resistantmSystems · 2025Article
- Efficacy of a commercial bacteriophage cocktail against planktonic cells and both thin and thick biofilms of skin pathogens, measured using isothermal microcalorimetry.Frontiers in microbiology · 2025Article
- Repurposing pinaverium bromide against Staphylococcus and its biofilms with new mechanisms.AMB Express · 2024Article
- Antimicrobial and anti-biofilm activity of a thiazolidinone derivative againstMicrobiology spectrum · 2024Article
- TheMicroorganisms · 2024Article
- Thiazolidin-4-Ones as a Promising Scaffold in the Development of Antibiofilm Agents-A Review.International journal of molecular sciences · 2023Review
- In vitro antibiofilm and bacteriostatic activity of diacerein against Enterococcus faecalis.AMB Express · 2023Article
- The Regulations of Essential WalRK Two-Component System onJournal of clinical medicine · 2023Review
- In vitro activities of thiazolidione derivatives combined with daptomycin against clinical Enterococcus faecium strains.BMC microbiology · 2022Article
- Targeting Staphylococcus aureus and its biofilms with novel antibacterial compounds produced by Lactiplantibacillus plantarum SJ33.Archives of microbiology · 2021Article
- Antibacterial and anti-biofilm activities of histidine kinase YycG inhibitors against Streptococcus agalactiae.The Journal of antibiotics · 2021Article
- Biosurfactant synergized with marine bacterial DNase disrupts polymicrobial biofilms.Folia microbiologica · 2021Article
- Dehydroabietic Acid Microencapsulation Potential as Biofilm-Mediated Infections Treatment.Pharmaceutics · 2021Article
- Eradication of Acinetobacter baumannii Planktonic and Biofilm Cells Through Erythrosine-Mediated Photodynamic Inactivation Augmented by Acetic Acid and Chitosan.Current microbiology · 2021Article
- Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol AgainstFrontiers in microbiology · 2021Article
- Phenolic Compounds fromMolecules (Basel, Switzerland) · 2019Article
- MonitoringSensors (Basel, Switzerland) · 2018Article
- Antimicrobial and anti-biofilm activity of hexadentated macrocyclic complex of copper (II) derived from thiosemicarbazide against Staphylococcus aureus.Scientific reports · 2018Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Both Staphylococcus aureus and Staphylococcus epidermidis can form biofilms on natural surfaces or abiotic surfaces, such as medical implants, resulting in biofilm-associated diseases that are refractory to antibiotic treatment. We previously reported a promising antibacterial compound (Compound 2) and its derivatives with bactericidal and anti-biofilm activities against both S. epidermidis and S. aureus. We have further evaluated the antibacterial activities of four Compound 2 derivatives (H2-38, H2-39, H2-74 and H2-81) against 163 clinical strains of S. epidermidis and S. aureus, including methicillin-susceptible and methicillin-resistant strains, as well as biofilm-forming and non-biofilm-forming strains. The four derivatives inhibited the planktonic growth of all of the clinical staphylococcal isolates, including methicillin-resistant S. aureus and methicillin-resistant S. epidermidis and displayed bactericidal activities against both immature (6 h) and mature (24 h) biofilms formed by the strong biofilm-forming strains. The derivatives, which all target YycG, will help us to develop new antimicrobial agents against multidrug-resistant staphylococci infections and biofilm-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.